Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
– Company to present Phase III ECOSPOR IV data evaluating safety, efficacy and durability of investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection –
“These industry-leading conferences bring together the biggest and brightest minds in both infectious disease and gastroenterology, and we’re excited to present new findings related to our investigational microbiome therapeutic, SER-109,” said
Seres’ upcoming data presentations include:
IDWeek 2022: Oral Presentation: SER-109, an oral investigational microbiome therapy for the prevention of recurrent Clostridioides difficile infection (rCDI);
October 20, 8:50 – 9:00 AM EST; Lead Author: Barbara McGovern, MD
ACG 2022 Annual Meeting: Oral Presentation: Plenary Session 4A - Colon / IBD;
October 26, 9:50 AM– 10:00 AMEST; Lead Author: Sahil Khanna, MBBS, MS, FACG
Seres recently announced the completion of the Biologics License Application (BLA) submission to the
SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome. SER-109 is designed to prevent further recurrences of CDI by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. The SER-109 manufacturing purification process is designed to remove unwanted microbes, thereby reducing the risk of pathogen transmission beyond donor screening alone. The FDA has granted SER-109 Breakthrough Therapy designation and Orphan Drug designation for the prevention of rCDI.
For more information, please visit www.serestherapeutics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the potential approval of SER-109; the potential market for SER-109; the ultimate safety profile of SER-109; the anticipated indication of SER-109; and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the impact of the COVID-19 pandemic; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the